$0.500
-0.338 (-67.53%)Zum Schluss
- High
- 1.540
- Open
- 1.510
- VWAP
- 0.85
- Vol
- 5.90M
- Mkt Cap
- 4.10M
- Low
- 0.500
- Amount
- 4.99M
- EV/EBITDA, TTM
- 0.00
TC BioPharm Limited is a clinical-stage biopharmaceutical company. The Company is engaged in developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer, as well as developing gamma-delta T cell therapies for the treatment of infectious disease. The Company's platform technology allows the Company to design specific therapies to treat a range of cancers and infectious diseases with off-the-shelf allogeneic gamma-delta T cell (GDT) products. The Company’s pipeline includes OmnImmune and CAR-T programs. OmnImmune is an unmodified allogeneic gamma-delta T cell product being used for the treatment of acute myeloid leukemia (AML). The Company has completed a Phase II clinical trial. Its CAR-T programs include in-house and partner programs at the pre-clinical-stage focused on developing CAR modified allogeneic gamma delta T-cell products targeting solid and hematological indications.
Bewertungskennzahlen
Event-Zeitleiste
News
9.006-11NewsfilterTC BioPharm Announces Complete Response in Minimal Residual Disease (MRD) Patient
2.003-21BenzingaWhy TC Biopharm (TCBP) Stock Is Down Over 60% Today
- 7.003-21Newsfilter
TCBP Announces Transition from Nasdaq to OTC Markets
- 4.503-18Newsfilter
TCBP Announces Outsourcing Initiatives, Reducing Burn Rate and Overhead
8.503-08SeekingAlphaKey deals this week: Walgreens Boots, Honeywell, Amex and more
TCBP FAQ — answered by Alphio AI
TC BioPharm Limited is a clinical-stage biopharmaceutical company. The Company is engaged in developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer, as well as developing gamma-delta T cell therapies for the treatment of infectious disease. The Company's platform technology allows the Company to design specific therapies to treat a range of cancers and infectious diseases with off-the-shelf allogeneic gamma-delta T cell (GDT) products. The Company’s pipeline includes OmnImmune and CAR-T programs. OmnImmune is an unmodified allogeneic gamma-delta T cell product being used for the treatment of acute myeloid leukemia (AML). The Company has completed a Phase II clinical trial. Its CAR-T programs include in-house and partner programs at the pre-clinical-stage focused on developing CAR modified allogeneic gamma delta T-cell products targeting solid and hematological indications. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.